0353 GMT - ResMed's chief executive says he was always confident that the emergence of weight-loss drugs such as Ozempic would benefit his breathing-tech company. In 2023, ResMed's stock lost about 40% of its value in less than two months as analysts worried that medication would reduce demand for devices used to treat conditions including sleep apnea. Instead, ResMed CEO Mick Farrell says medication improved awareness of sleep apnea, lifting the number of patients seeking treatment of all forms. ResMed's stock has almost doubled in value since September 2023. "I was happy to be in the conversation with cardiovascular disease, stroke, COPD [chronic obstructive pulmonary disease], sleep apnea and all these chronic diseases. I knew it was huge for awareness." (stuart.condie@wsj.com)
(END) Dow Jones Newswires
January 30, 2025 22:53 ET (03:53 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。